A61K 39/001114
Cd74, ii, mhc class ii invariant chain or mhc class ii gamma
Official title: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
A61K39/001114 (Cd74, ii, mhc class ii invariant chain or mhc class ii gamma) appears on 105 US grants and 161 published applications in this corpus.
Search patents in A61K- Granted patents
- 105
- Published applications
- 161
- Assignees
- 44
- Inventors
- 148
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 4 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 1 | 2 |
| 2015 | 0 | 1 |
| 2016 | 2 | 5 |
| 2017 | 0 | 2 |
| 2018 | 0 | 5 |
| 2019 | 5 | 13 |
| 2020 | 29 | 47 |
| 2021 | 35 | 29 |
| 2022 | 7 | 8 |
| 2023 | 7 | 20 |
| 2024 | 7 | 8 |
| 2025 | 5 | 9 |
| 2026 | 4 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and vaccines for inducing immune responses to multiple different MHC molecules12 May 2026US 12,622,956 B2Mayo Foundation for Medical Education and Research
- Cancer vaccines24 Mar 2026US 12,582,609 B2ModernaTX, Inc.
- Teleost invariant chain cancer vaccine17 Mar 2026US 12,576,143 B2Nouscom AG
- Compositions for treatment of diffuse intrinsic pontine glioma24 Feb 2026US 12,558,407 B2University of Florida Research Foundation, Inc.
- Multimeric T-cell modulatory polypeptides and methods of use thereof2 Dec 2025US 12,485,183 B2Cue Biopharma, Inc.
- Design method and production method for nucleic acid construct and protein complex20 Aug 2026US 2026/0240966 A1University of Tsukuba
- Compositions for treatment of diffuse intrinsic pontine glioma20 Aug 2026US 2026/0240971 A1University of Florida Research Foundation, Inc.
- Cancer vaccines25 Jun 2026US 2026/0174704 A1ModernaTX, Inc.
- Cancer vaccines25 Jun 2026US 2026/0174705 A1ModernaTX, Inc.
- Cancer vaccines4 Jun 2026US 2026/0151351 A1ModernaTX, Inc.
Most cited
By later US patents
- Dock-and-lock (DNL) vaccines for cancer therapy68US 7,901,680 B2IBC Pharmaceuticals, Inc. · 2011
- Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity42US 8,551,480 B2IBC Pharmaceuticals, Inc. · 2013
- Effective generation of tumor-targeted T cells derived from pluripotent stem cells16US 10,370,452 B2Memorial Sloan Kettering Cancer Center · 2019
- Compositions and methods for immunotherapy9US 10,654,928 B2Memorial Sloan Kettering Cancer Center · 2020
- Multimeric T-cell modulatory polypeptides and methods of use thereof8US 11,878,062 B2Cue Biopharma, Inc. · 2024